AstraZeneca

MedImmune, is a company that produces Synagis, a drug for the prevention of respiratory infections in infants, which accounted for US$ 1.06 billion of its US$ 1.2 billion in revenue for 2005, and FluMist, a nasal spray influenza vaccine introduced in 2004. MedImmune has over 120 drugs in development for conditions including lupus, COPD, asthma, and many types of cancer.

MedImmune

AstraZeneca Plc is a holding company, which engages in the research, development, manufacture, and commercialization of prescription medicines. The company was founded on June 17, 1992 and is headquartered in Cambridge, the United Kingdom.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Alexion Pharma

With UK approval, the $39 billion deal for rare disorders biotech company Alexion Pharmaceuticals is set to close on July 21.

With the Alexion Acquisition Set to Close This Quarter, Is AstraZeneca a Buy?

Burberry Group PLC

Rio Tinto plc Sponsored

Friday's session was marked with a cluster of corporate news that was sending shares of three big heavyweights lower.

London Markets: Burberry, Rio Tinto and AstraZeneca keep a lid on London stock gains

FibroGen

AstraZeneca PLC has disclosed Friday that a U.S. Food and Drug Administration advisory committee has voted 13 to 1 not to support approval of roxadustat for the treatment of anaemia in chronic kidney disease (CKD) in non-dialysis dependent adult patients. Shares of FibroGen Inc. , which was AstraZeneca's partner in developing roxadustat, plummeted 34.1% in premarket trading, while AstraZeneca's U.S.-listed shares edged up 0.4%.

AstraZeneca says FDA advisory committee won't support CKD treatment for approval, partner FibroGen stock plunges

AstraZeneca PLC (LON:AZN) is facing rejection from the US drug regulator for its application for a novel new drug to treat anaemia resulting from chronic kidney disease. The Food and Drug Administration's (FDA) Cardiovascular and Renal Drugs Advisory Committee voted against approving Roxadustat on the basis of its benefit-risk profile for both non-dialysis dependent and dialysis-dependent adult patients.

AstraZeneca and FibroGen face FDA red light over anaemia drug

AstraZeneca (AZN) obtains UK Competition and Markets Authority's permission for the impending acquisition of Alexion. The deal is expected to close on Jul 21, 2021.

AstraZeneca (AZN) Gets Clearance in UK for Alexion Acquisition

AstraZeneca PLC's (LON:AZN) expects to complete its £27.5bn acquisition of rare disease specialist Alexion Pharmaceuticals Inc next week after getting the go-ahead from UK authorities. The UK Competition and Markets Authority said this morning that it cleared the proposed deal, deciding not to refer it to a Phase 2 investigation.

AstraZeneca gets final go-ahead for £27.5bn Alexion acquisition

Britain's competition regulator said on Wednesday it has cleared AstraZeneca's $39 billion buyout of U.S.-based Alexion after it decided not to initiate a broader probe into the deal following its initial assessment.

British watchdog clears AstraZeneca's $39 billion buyout of Alexion

Ahead of Thursday's meeting of the FDA's Cardiovascular and Renal Drugs Advisory Committee, the agency is raising fresh doubts on the safety of AstraZeneca Plc's (NASDAQ: AZN) and FibroGen Inc's (NASDAQ: FGEN) anemia drug roxadustat. FDA staffers flagged concerning evidence of blood clotting, when compared with placebo in nondialysis-dependent patients but also when compared against Amgen Inc (NASDAQ: AMGN) and Johnson & Johnson's (NYSE: JNJ) Epogen/Procrit, "which is itself known to pose these risks," in dialysis-dependent patients.

Ahead Of AdComm AstraZeneca, FibroGen's Roxadustat Hit With Safety, Efficacy Questions

Johnson & Johnson

The blood clotting, which some scientists are now calling vaccine-induced immune thrombotic thrombocytopenia, or VITT, has been linked to both shots.

J&J, AstraZeneca explore modifying Covid vaccines in response to rare blood clot issue, report says

BioNTech SE

Moderna

Novavax

Pfizer

Based on company forecasts, Wall Street estimates, and author guestimates, the top coronavirus vaccine developers will bring in billions of dollars in sales this year.

COVID-19 Vaccines: How Much Revenue Will Each Drugmaker Generate in 2021?

Those already fully vaccinated with Sinovac will be offered a booster dose of an mRNA vaccine, which includes Pfizer-BioNTech or Moderna shots.

Thailand To Mix Sinovac And AstraZeneca Shots As Concerns Over Chinese Vaccine Escalate

Broadcom

These stocks offer the best of both worlds: rapid sales growth and a market-topping dividend yield.

3 of the Fastest-Growing Dividend Stocks on the Planet

F-star partners with AstraZeneca for its novel STING inhibitor compounds. Resultantly, F-star's shares rise 9.1%.

F-star (FSTX), AstraZeneca Team Up for Novel STING Inhibitors

VANCOUVER, British Columbia, July 09, 2021 (GLOBE NEWSWIRE) -- EnWave Corporation (TSX-V:ENW | FSE:E4U) (“EnWave”, or the “Company”) announces that it has signed a material transfer agreement (“MTA”) with MedImmune Limited, an affiliate of AstraZeneca AB (LSE/STO/Nasdaq: AZN) (“AZ”), to facilitate the trialing of EnWave's Radiant Energy Vacuum (“REV”) technology for the dehydration of liquid monoclonal antibody formulations. AZ will send proprietary materials to EnWave's testing facility in Vancouver, Canada to conduct initial proof-of-concept trials. If successful, the two companies intend to negotiate a more robust agreement to allow for further research and development activities.

EnWave Signs Material Transfer Agreement with AstraZeneca to Trial Radiant Energy Vacuum Technology for Pharmaceutical Dehydration

AbbVie

Bayer AG

AstraZeneca (AZN), AbbVie (ABBV) and Bayer (BAYRY) are three large drug sector companies worth buying now.

3 Big Drugmakers to Buy Ahead of the Q2 Earnings Season (Revised)

Daiichi Sankyo Co Ltd

Daiichi Sankyo Co Ltd (OTC: DSKYF) and AstraZeneca plc (NASDAQ: AZN) have dosed the first patient in DESTINY-Gastric04, Phase 3 trial of Enhertu (trastuzumab deruxtecan) for gastric or gastroesophageal junction (GEJ) adenocarcinoma. The trial will evaluate the safety and efficacy of Enhertu compared to ramucirumab/paclitaxel combination therapy in patients with HER2 positive metastatic or unresectable gastric or GEJ adenocarcinoma with disease progression on or after a trastuzumab-containing regimen.

Daiichi Sankyo - AstraZeneca Start Dosing In Head-To-Head Stomach Cancer Trial With Enhertu

Ford Motor Company

F-star Therapeutics Inc (NASDAQ: FSTX)  has entered into an exclusive licensing agreement with AstraZeneca plc (NASDAQ: AZN) for research, development, and commercialization of next-generation Stimulator of Interferon Genes (STING) inhibitor compounds. Under the terms of the agreement, AstraZeneca is granted exclusive access to F-star's novel preclinical STING inhibitors.

F-star Therapeutics Stock Jumps On Licensing Pact For STING Inhibitors With AstraZeneca

Per the latest CDC data, the Delta variant now makes up almost half of the COVID-19 cases in the United States.

Vaccine Stocks Fall as Delta Becomes Dominant Variant in US

Amgen

The FDA has accepted for review Amgen Inc's (NASDAQ: AMGN) marketing application seeking approval for tezepelumab to treat asthma.  Amgen is developing Tezepelumab in collaboration with AstraZeneca plc (NASDAQ: AZN).

Amgen - AstraZeneca's Asthma Candidate Under Priority Review With FDA

AstraZeneca has a Covid vaccine, but the company is also a specialist in cancer treatments, and it supplies medicine for a host of other diseases.

Vaccine Maker AstraZeneca's Drug Pipeline Could Boost the Stock

AstraZeneca plc (LON:AZN) announced that an asthma treatment developed with Amgen has been granted priority review in the US. Tezepelumab reached all objectives in late-stage trials and showed better results than placebo.

AstraZeneca receives US priority review for asthma candidate

AstraZeneca (AZN) obtains European Commission's permission for the acquisition of Alexion. The deal is expected to close in the third quarter of 2021.

AstraZeneca (AZN) Gets EC's Clearance for Alexion Acquisition

3 Big Drugmakers to Buy Ahead of the Q2 Earnings Season

UBS has prepared a list of European stocks ahead of results season where it expects the numbers to exceed expectations. The Swiss bank said there had been a spate of companies beating consensus forecasts as the world has begun to emerge from lockdown.

AstraZeneca is a key pick, but which other stocks are on this top bank's 'buy' list?

AstraZeneca PLC (LON:AZN) announced it has received EU approval for the US$39bn (£27.5bn) acquisition of Alexion Pharmaceuticals, Inc., expected to complete in the third quarter. The pharma giant has already received approval in the US, Canada, Brazil, Russia and Japan but is still waiting for the green light from the UK.

AstraZeneca receives EU clearance for £27.5bn Alexion acquisition

News for AstraZeneca Stock (AZN)